BioIntel is now The Catalyst Brief.
The Catalyst Brief
Coverage

Biotech Innovation

Gene therapy, CRISPR, synthetic biology and emerging platforms. Separating what is real from what is hype, and what actually translates.

Page 2 of 15

Archive

Researchers Introduce ScSTAMP-Seq For Spatially Resolved Single-Cell Multiomics In Human EmbryoidsSep 27, 2026

Researchers Introduce ScSTAMP-Seq For Spatially Resolved Single-Cell Multiomics In Human Embryoids

The method uses cholesterol-conjugated, photocleavable hashtag oligonucleotides and patterned light exposure to stamp spatial coordinates onto individual cells before single-cell multiome sequencing. The strategic signal is less about a single biological finding than about a modular workflow that aims to narrow the tradeoff between spatial context and scalable single-cell readouts.

The Catalyst Brief
Otsuka And Ionis Post Phase 3 Ulefnersen Win In FUS-ALS, Setting Up FDA Talks In A Tiny MarketSep 23, 2026

Otsuka And Ionis Post Phase 3 Ulefnersen Win In FUS-ALS, Setting Up FDA Talks In A Tiny Market

The Fusion study met its primary endpoint, with patients on ulefnersen performing significantly better than placebo on a Week 72 measure that combined functional impairment and survival. The readout matters scientifically because it targets a defined disease driver, but its business impact is likely to be limited by the very small patient population.

The Catalyst Brief
Beacon Posts XLRP Trial Win For Laru-Zova, Opening An FDA Filing Path In Rare Vision LossSep 21, 2026

Beacon Posts XLRP Trial Win For Laru-Zova, Opening An FDA Filing Path In Rare Vision Loss

In the 85-patient Vista study, 24.1% of patients in the low-dose arm and 31% in the high-dose arm met the responder definition for improved visual acuity under low light, versus none in the control group. Beacon said it plans to start and finish a rolling biologics license application to the FDA before the year’s end, while also pursuing approval in the European Union and the U.K.

The Catalyst Brief
Definium Posts Third Late-Stage DT120 Win, Setting Up An FDA Filing In AnxietySep 14, 2026

Definium Posts Third Late-Stage DT120 Win, Setting Up An FDA Filing In Anxiety

In the Panorama study, a 100 microgram dose of DT120 reduced Hamilton Anxiety Rating Scale scores by 9.8 points at week 12, versus 4.7 points for placebo. Definium also used a 50 microgram arm to address functional unblinding concerns that have become a live regulatory issue in psychedelic development.

The Catalyst Brief
Cullinan And Taiho Post 14.5-Month PFS For Zipalertinib Combo, Pressing Rybrevant In EGFR Exon 20 NSCLCSep 14, 2026

Cullinan And Taiho Post 14.5-Month PFS For Zipalertinib Combo, Pressing Rybrevant In EGFR Exon 20 NSCLC

The Rezilient3 interim analysis showed statistically significant progression-free survival and higher response rates for zipalertinib combined with chemotherapy in previously untreated advanced non-small cell lung cancer with EGFR exon 20 insertion mutations. With a later-line FDA decision expected next February, Taiho is now planning discussions with global health authorities and the FDA about the front-line data.

The Catalyst Brief
Platinum Chemotherapy In Childhood Adds About 2,200 Liver Mutations Per Sample, Study FindsSep 11, 2026

Platinum Chemotherapy In Childhood Adds About 2,200 Liver Mutations Per Sample, Study Finds

The study focused on cisplatin and carboplatin in children who received platinum therapy followed by surgery to remove liver tumors. Its immediate implication is not a change to current use of these drugs, but a stronger basis for long-term monitoring and, eventually, for designing treatments that spare healthy tissue more effectively.

The Catalyst Brief
Caspian Launches With $50 Million And Lilly Backing To Push Menin Inhibitor Into DiabetesSep 9, 2026

Caspian Launches With $50 Million And Lilly Backing To Push Menin Inhibitor Into Diabetes

The new company was created specifically to move a next-generation menin inhibitor into diabetes, with funding led by BVF Partners and participation from Eli Lilly, Kura and other investors. Caspian also plans to advance a second menin program for diabetes and cardiometabolic conditions while preparing KO-7246 for IND-enabling work and initial clinical proof-of-concept.

The Catalyst Brief

Other beats

AI in Drug Discovery

Machine learning, predictive models and computational biology: how AI is changing discovery workflows and probability of success.

Biopharmaceutical Industry

Drug development, clinical trials and industry dynamics. What changes timelines, risk and competitive positioning.

Healthcare Investment

Where capital is flowing and why the tape moves, across funding rounds, M&A, IPOs and market analysis.

Medical Technology

Digital health, diagnostics and medical devices, and the signals that matter for adoption, reimbursement and outcomes.

Regulatory & Policy

FDA actions, approvals, policy shifts and compliance: how the rules change timelines and probability.